Loading organizations...
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing novel therapies for central nervous system disorders. It focuses on neurodegenerative diseases like Alzheimer's and Parkinson's, employing advanced scientific approaches. Their core work identifies disease-modifying treatments for significant unmet medical needs, utilizing expert teams for discovery and translational research.
SciNeuro was established in 2020 by Dr. Min Li, a distinguished neuroscientist and former professor at Johns Hopkins Medicine. Dr. Li founded the company recognizing that innovative strategies were essential to overcome complex CNS disease challenges. His vision aimed to develop therapies profoundly impacting the progression of these debilitating conditions.
The company's efforts target patients afflicted with neurodegenerative conditions, where effective treatment options are scarce. SciNeuro's mission is to advance understanding of brain disorders and deliver transformative solutions, improving patient outcomes. They are committed to progressing neuroscience through rigorous research, bringing new treatments from discovery to clinical development.
SciNeuro has raised $100.0M across 1 funding round.
SciNeuro has raised $100.0M in total across 1 funding round.
SciNeuro has raised $100.0M in total across 1 funding round.
SciNeuro's investors include ARCH Venture Partners, Sequoia Capital China.
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company developing novel therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.[1][3][4] It targets key disease mechanisms—neurovascular inflammation, proteinopathy (e.g., beta amyloid, LRRK2), and immune response—using a proprietary blood-brain barrier (BBB) shuttle platform to enhance drug delivery and efficacy.[3][4][6] The company serves patients with CNS disorders, addressing unmet needs in disease-modifying treatments amid rising global burdens from aging populations.[1][4] Founded in 2020 and headquartered in Rockville, MD, SciNeuro recently raised $53 million in equity financing led by LAV and ARCH Venture Partners, plus a $5 million grant from The Michael J. Fox Foundation, fueling pipeline advancement from discovery to clinical stages.[2][3]
SciNeuro was founded in 2020 by Min Li, PhD, who serves as CEO, driven by advances in neuroscience genetics and pathophysiology enabling a "golden age" of brain disease treatments.[1][2][3] Li assembled an expert team of discovery scientists, translational researchers, and industry leaders to translate scientific insights into therapies, emphasizing global collaborations.[1][5] Early momentum includes building a pipeline across neurodegeneration pathways and securing a $5 million non-dilutive grant from The Michael J. Fox Foundation for Parkinson's research, culminating in the pivotal $53 million financing announced December 4, 2025, which also brought on Hogan Wan as CFO with deep biopharma finance experience.[2][3]
SciNeuro rides the wave of rapid progress in human genetics, genomics, and biomarkers uncovering neurodegeneration culprits, timing perfectly with an aging global population facing escalating brain disease burdens.[1][4] Market forces like ARCH Venture Partners' focus on high-risk CNS investments—despite lower success rates—validate its approach, alongside grants from foundations like MJFF signaling ecosystem support.[2] By prioritizing BBB penetration and multi-mechanism therapies, SciNeuro influences biotech's shift toward disease-modifying CNS drugs, potentially reshaping treatments for Alzheimer's, Parkinson's, and vascular dementia in a field long plagued by failures.[2][4]
SciNeuro's $53 million raise positions it to advance clinical programs and expand discovery, with near-term milestones in Parkinson's (LRRK2) and Alzheimer's (beta amyloid) pathways.[2][3] Trends like AI-enabled genetics and advanced imaging will amplify its platform, while partnerships could accelerate global trials. Its influence may grow as a CNS leader if early data de-risks the pipeline, transforming scientific enigmas into therapies that restore patient quality of life—echoing its mission to decipher brain diseases and fuel a new treatment era.[1]
SciNeuro has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series A in December 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2020 | $100.0M Series A | ARCH Venture Partners, Sequoia Capital China |